Company news

Sarepta Therapeutics, Inc. news in 2026

Sarepta Therapeutics, Inc.'s news releases, calls and decks from 2026, newest first.

View company

Sarepta Therapeutics Announces Third Quarter 2026 Financial Results and Recent Corporate Developments

November 5, 2026

Sarepta Therapeutics to Present at Upcoming Investor Conferences

October 26, 2026

Sarepta Therapeutics to Announce Third Quarter 2026 Financial Results

October 22, 2026

Sarepta Therapeutics Presents New Preclinical Data Demonstrating Robust Knockdown of Pathogenic DMPK RNA in the Nucleus with SRP-1003 in DM1 at 2026 Oligonucleotide Therapeutics Society Annual Meeting

October 14, 2026

Sarepta Therapeutics Presents New Data at 2026 World Muscle Society Annual Congress Demonstrating Safety and Clinically Meaningful Functional Benefit of ELEVIDYS (delandistrogene moxeparvovec) in Older Ambulatory Patients with Duchenne

September 30, 2026

Sarepta Therapeutics Announces Presentations at 2026 World Muscle Society Annual Congress

September 25, 2026

Sarepta Therapeutics to Present New Data from its Neuromuscular Portfolio at 27th Annual Neuromuscular Study Group Scientific Meeting

September 24, 2026

Sarepta Therapeutics Announces Recipients of Route 79, The Duchenne Scholarship Program, for the 2026-2027 Academic Year

September 8, 2026

Sarepta Therapeutics to Present at the Morgan Stanley 24th Annual Global Healthcare Conference

August 31, 2026

Sarepta Therapeutics Announces Second Quarter 2026 Financial Results and Recent Corporate Developments

August 5, 2026

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(4)

July 30, 2026

Sarepta Therapeutics Appoints Michael Severino, M.D., Chief Executive Officer

July 27, 2026

Sarepta Therapeutics to Announce Second Quarter 2026 Financial Results

July 22, 2026

Sarepta Announces FDA Acceptance of sNDAs for AMONDYS 45® and VYONDYS 53®

June 30, 2026

Sarepta Therapeutics to Participate in Upcoming Investor Conferences

June 1, 2026

Sarepta Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference

May 13, 2026

Sarepta Therapeutics Announces First Quarter 2026 Financial Results and Recent Corporate Developments

May 6, 2026

Sarepta Therapeutics to Announce First Quarter 2026 Financial Results

April 22, 2026

Sarepta Announces First Clinical Data from siRNA Pipeline Targeting FSHD1 and DM1

March 24, 2026

Sarepta to Share First Clinical Data from siRNA Pipeline Targeting FSHD1 and DM1

March 23, 2026

Sarepta Provides Regulatory Update on AMONDYS 45® and VYONDYS 53®

March 18, 2026

Sarepta Announces that Screening and Enrollment are Underway in ENDEAVOR Cohort 8 to Evaluate Enhanced Immunosuppression Regimen as Part of ELEVIDYS Gene Therapy for Non-Ambulant Individuals with Duchenne

March 15, 2026

Sarepta Therapeutics Announces Call for Applications for the 9th Annual Route 79, The Duchenne Scholarship Program

February 26, 2026

Sarepta Therapeutics to Present New Long-Term and Safety Data Across Gene Therapy and Exon-Skipping Programs at 2026 Muscular Dystrophy Association Clinical & Scientific Congress

February 26, 2026

Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Recent Corporate Developments

February 24, 2026

Sarepta Therapeutics Announces Commercial Launch of ELEVIDYS in Japan

February 24, 2026

Sarepta Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference

February 24, 2026

Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2025 Financial Results

February 11, 2026

Sarepta Therapeutics Announces Approval of Clinical Trial Application for SRP-1005, Its Investigational Treatment for Huntington’s Disease

February 4, 2026

Sarepta Announces Positive Topline Three-Year EMBARK Results Showing ELEVIDYS Significantly Slows Disease Progression on Key Functional Measures in Ambulatory Duchenne Patients

January 25, 2026

Sarepta Therapeutics to Report 3-Year Topline Data from EMBARK Study of ELEVIDYS Gene Therapy in Ambulatory Individuals with Duchenne Muscular Dystrophy

January 23, 2026

Sarepta Reports Preliminary* Fourth Quarter and Full-Year 2025 Net Product Revenues

January 12, 2026

Sarepta Therapeutics Announces Submission of Clinical Trial Application for SRP-1005, its Investigational Treatment for Huntington’s Disease

January 7, 2026

Sarepta Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

January 4, 2026

Calls in 2026

Decks in 2026